Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Download Data

Tela Bio Inc Liabilities to Equity Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 78.27%

Tela Bio Inc Liabilities to Equity Ratio 3 year CAGR is 78.27% for the Trailing 12 Months (TTM) ending March 31, 2024, a 44.30% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tela Bio Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -2.60, a -212.98% change year over year.
Tela Bio Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 2.30, a 226.90% change year over year.
Tela Bio Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.71, a 199.35% change year over year.
Tela Bio Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.71, a -21.64% change year over year.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends